Forbes March 12, 2025
In the last few weeks, Moderna announced that it’s cutting 10% of roles in its digital departments, just months after scaling back research spending by 20%. Biogen took a similar approach in January, reducing its research team. Johnson & Johnson laid off over 200 employees at its headquarters in October. And they’re far from alone – large pharma companies and dozens of smaller biotech firms are slashing jobs or shutting down entirely as the industry faces continued financial pressures.
These layoffs reflect two distinct forces shaping the pharmaceutical sector. On one hand, companies are making adjustments tied to natural business cycles – products lose exclusivity, some assets fail clinical trials and research programs are shut down when data doesn’t support...
Today's Sponsors
Today's Sponsor